Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DNA · against 557 other Healthcare companies listed in US-listed
Ranked #412 of 558 · scores higher than 24% of peers
Bars: peers in each 10-point band of the profitability score114 peers with a profitability score of 10–19, including DNA · Click a bar to see the companies
Mainly because of its return on invested capital and operating margin, which are weaker than most Healthcare peers.
| Metric | DNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 517 reported | -72.0% | -7.0% | 18% | 33% | |
| Operating marginHigher is better · 479 reported | -231.1% | -2.4% | 19% | 33% | |
| Return on assetsHigher is better · 582 reported | 2.2% | -7.8% | 68% | 33% | |
| Return on equityHigher is better · 531 reported | -59.9% | -19.7% | 23% | Context only | |
| Gross marginHigher is better · 601 reported | 68.0% | 43.9% | 70% | Context only |
| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 595M USD | 99 | 97 | |
| 1 | 433M USD | 99 | 81 | |
| 1 | 17.9B USD | 99 | 76 | |
| 1 | 52.9B USD | 99 | 57 | |
| 1 | 578M USD | 99 | 73 | |
| 401 | 2.3B USD | 14 | 27 | |
| 412 | 198M USD | 13 | 10 | |
| 412 | 3.7B USD | 13 | 31 | |
| 412 | 968M USD | 13 | 37 | |
| 412 | 725M USD | 13 | 19 | |
| 412 | 1.4B USD | 13 | 38 | |
| 412 | 5.7B USD | 13 | 30 | |
| 412 | 27M USD | 13 | 24 | |
| 412 | 1.4B USD | 13 | 39 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score